anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
The invention discloses a metal-ion-doped potassium lanthanum fluoride fluorescent material, and a preparation method thereof. The invention relates to the field of up-conversion luminescent materials. According to the invention, under a hydrothermal condition, KLaF4 is adopted as a substrate material; and proper amounts of a rare earth activator erbium, a sensitizer ytterbium and metal ions are doped into the substrate, such that up-conversion luminescent nano-particles which can be applied in the fields such as bio-probes, solid-state lasers and solar cells can be prepared. Through controlling the doping concentrations of different metal ions (Al&lt;3+&gt;, Na&lt;+&gt; or Li&lt;+&gt;), the fluorescence enhancement multiple of KLaF4:Yb&lt;3+&gt;/Er&lt;3+&gt; can be controlled at 3-7. The invention adopts the hydrothermal reaction, such that the process is simple. The prepared nano-particles have a crystalline state, and have good dispersion and high luminous intensity.
A method for enhancing the overall beneficial immune system response in a host that works in conjunction with the host&#39;s natural immune system response to simultaneously enhance the host&#39;s ability to eliminate infectious microbes while suppressing the toxicity of the immune system response to the host. The method utilizes the non-enzymatic formation of allicin in response to the localized generation of H2O2 by immune system cells (such as neutrophils) to simultaneously increase the antimicrobial effect while reducing the cytotoxicity to the host. It is shown that enzymes can be reversibly inhibited that would not normally be sensitive to deactivation by a thiol-disulfide exchange reaction. This results in part from the recognition that deactivation of SH dependant enzymes by allicin does not take place by the previously attributed mechanism of thiol-disulfide exchange reactions. Allicin, cysteine, and related organosulfur compounds have a variety of antimicrobial and immunomodulatory properties that work together with the host&#39;s immune system in the prevention and treatment of disease. Prophylactic and therapeutic treatment is provided by administering an allium-related organosulfur compound such that a localized thiosulfinate is caused to be non-enzymatically formed in response to localized generation of H2O2 by the activated immune system cells. Allicin, cysteine and related organosulfur compounds may be simultaneously delivered in an efficient manner through the use of protein-bound S-AllylMercaptoCysteine (SAMC) or similar prodrugs.
PURPOSE:To provide a cerebral aneurysm rhegma having no anxious action such as an adverse reaction and toxicity, by containing the human blood coagulation XIII factor as a main component. CONSTITUTION:The objective agent is obtained by preparing by a conventional method a composition containing as an active ingredient the human blood coagulation XIII factor obtained from human placentas or blood plasma as a raw material. The agent is preferably prepared in a form of injections but can be also prepared in a form of tablets, capsules, suppositories, etc. The agent is administered in a dose of &lt;= approximately 5,000 units a day for usually 5-7 days. The concentration of the injection is preferably approximately 250 units/4ml. The rhegma of the cerebral aneurysm now has no therapeutic method except an operation and can not be solved when the application of the operation is impossible due to a high aged patient, the existence of the cerebral aneurysm in a deep position and a large size, etc. But the agent prevents the rhegma.
A medical system for remote monitoring, analysis and prognosis of the patient&#39;s condition by series of at least first-lead electrocardiograms (ECGs) recorded for each patient from a plurality of observed patients, comprises: a unit for gathering in a database of the medical system for each of the observed patients a series of his ECGs marked with patient identifiers; a unit for extracting on doctor&#39;s request from the gathered database an ECG subset of a target group of patients, which are combined in said system into the target group in accordance with restrictions specified in the doctor&#39;s request and at least one of the identifiers in accordance with the examination purpose. A unit for clustering the extracted ECG subset sequentially combines all the ECGs extracted to the subset to at least one cluster based on the feature of similarity of their forms using a clustering method. A unit for determining an ECG form similarity measure in the space of ECG form features associates each ECG from the database of the medical system with a discretized ECG (DECG), which is a point having coordinates in at least one space of ECG form features. A unit for generating STANDARDS generates a corresponding STANDARD for each cluster. A unit for assessing the patient&#39;s condition assesses variation in the observed patient&#39;s condition over time by temporal variation in the distances between each newly received DECGs in the patient&#39;s DECG series and the assigned at least one STANDARD. A unit for predicting the observed patient&#39;s condition predicts the most probable future condition of the patient on the basis of &#34;history of observations&#34;. A unit for imaging the patient&#39;s condition displays the dynamics of variation in distances of the patient&#39;s newly received ECGs as a displacement of cardiogram geometric paths between the assigned STANDARDS.
Provided is a care support system which can ensure an appropriate response by care workers, etc. by promptly notifying events of persons in need of care, etc. while reducing network traffic to thereby reduce the burden on the care workers, etc. and quickly ensure safety of the persons in need of care. A sensor box SB itself determines that a subject has tripped and fallen or fallen from somewhere on the basis of image data corresponding to the subject&#39;s state. Thus, compared, for example, to when a management server SV determines the fall, the need to send a large amount of image data is eliminated so that traffic is limited and internet congestion is avoided. Further, a ring buffer 16 overwrites and stores the image data obtained by a camera 112 for a certain period of time, and when an SB control processing unit 14 determines that a specific event (a fall) has occurred to a subject Ob on the basis of the image data, the SB control processing unit 14 cuts out a portion of the image data stored in the ring buffer 16 and saves the same in a temporary retirement buffer 17. Thus, by viewing, after the event, the image data saved in the temporary retirement buffer 17, it can be accurately determined under what circumstance the specific event occurred to enable appropriate measures to be taken and to prevent the same thing from happening again.
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain a gel-like bleaching material composition for teeth causing neither sticking to a spatula or vessel nor cobwebbing as a conventional problem in the operability for such bleaching materials, good in the adhesion to teeth surfaces and causing no spills from a tray.  &lt;P&gt;SOLUTION: This gel-like bleaching material composition for teeth comprises 60-90 pts. wt. of a polyhydric alcohol as the main solvent, 0.5-15 pt(s). wt. of a methyl vinyl ether/maleic anhydride copolymer as the thickening agent and 1-25 pt(s). wt. of urea peroxide as the bleaching component. In this composition, the methyl vinyl ether/maleic anhydride copolymer to be used is neutralized within pH5-7 in an anhydrous condition, and it is preferable that the copolymer is crosslinked with 1,9-decadiene and accounts for ≥20 wt.% of the thickening agent formulated in this composition.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an aqueous composition having an excellent antibacterial, bacteriostatic, fungicidal and/or fungistatic effect even when the protamine content is small by synergistically improving antibacterial, antiseptic and preserving effects of protamine and boric acid by a simple method.  &lt;P&gt;SOLUTION: The antibacterial, bacteriostatic, fungicidal and/or fungistatic composition containing boric acid at high concentration relative to protamine can be further incorporated with polysorbates and/or edetic acids. Specifically, boric acid is contained in an amount of 6-630,000 pts.wt. per 1 pt.wt. of the protamine.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
PROBLEM TO BE SOLVED: To obtain a fat digesting enzyme-containing liquid medicine having stably retained enzyme activity. SOLUTION: This enzyme-containing internal liquid medicine contains a polyvinyl pyrrolidone and a fat digesting enzyme solution (e.g. lipase AP6) and has preventing effect on sterile filter membrane adsorption. The liquid medicine is further mixed with a water-soluble component of a crude medicine to give the objective enzyme-containing internal liquid medicine having preventing effect on sterile filter membrane adsorption and preventing effect on precipitation of the enzyme. The minimum amount of the fat digesting enzyme agent mixed is preferably &gt;=50 units per day and that of the polyvinyl pyrrolidone mixed is 0.05-5W/V %. The liquid medicine is mixed with 0.2-10W/V % of an essence, liquid essence or tincture of cinnamon bark, clove, gentian, SYOUKYOU (rhizome of Zingiber officinale), ginseng, KOUBOKU (Magnolia officinalis), etc.  The enzyme-containing internal liquid medicine is useful as an internal medicine for stomach and bowels, having effective action of the fat digesting enzyme on indigestion, a dull feeling in the stomach caused by indigestion, an undesirable condition in the stomach, etc., further showing healthy effect by adding the crude medicine.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a face powder, especially a loose powder having adhesiveness and spreadability to enable a simple cosmetical application comprising the treatment of the face with a lotion, the application of a cream and the makeup with the powder.  &lt;P&gt;SOLUTION: Although the whiteness of a pigment such as zinc white, talc and titanium white is not inferior to a lead-based face powder comprising lead white, it seems that the pigment is considerably inferior in the adhesiveness and spreadability to the lead-based powder. In fact, almost all face powder is used in a liquefied form called as a foundation and having rich oiliness, and the adhesiveness and spreadability are relied upon the use of a solvent. However, the uniform application of the liquid foundation as thin as possible is most difficult work necessitating a long experience. A white pigment having good adhesiveness and spreadability comparable to lead white is necessary for applying in the form of a clean, thin and uniform film in a short time. The reason of good adhesiveness and spreadability of lead white as a loose powder is supposed to be the weight of the lead powder, and the search for a white powder of a non-toxic heavy metal as a substitute for lead powder resulted in the finding of barium sulfate. Especially, precipitated barium sulfate has uniform particle size. The weight of barium sulfate is 233 g which is comparable to that of the lead white of 258 g. Furthermore, barium sulfate is not absolutely insoluble, but scarcely soluble in water. Based on the above findings, it has been convinced that a face powder group composed mainly of fine loose powder can be developed to enable the makeup and redo makeup easily without restriction of the time and place. The development of the face powder promises the innovation of the nature of the cosmetics from the use in front of a dressing table of a room to the portable use.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
PURPOSE:To obtain the titled cosmetic, by making cosmetic melt flow into one of a pair of templates having semicircular cylindrical dent channels, solidifying it, bringing the other template into contact with the template, making a glossy cosmetic flow into dent channels, solidifying it to give bonded core materials, using them. CONSTITUTION:First, the flat board 3 is brought into contact with the dent channels 2 of the template 1, stood so that the dent channels 2 are stood and arranged, and the cosmetic melt a is made to flow into the dent channels 2. After the melt a is cooled and solidified, the flat board 3 is released, the template 1&#39; is brought into contact with the template in such a way that the dent channels are faced each other, the melt b for gloosy (pearl) cosmetic is made to flow into the dent channels 2&#39;, cooled and solidified, to give core materials wherein two cores are arranged in parallel. The core materials are superimposed to make combinations with a pair, which are inserted into holes between wood boards, pressure is applied to the boards, the core materials are bonded, and the boards are cut into pencil forms, to give the titled cosmetic. Since one pencil has two cores for two purposes, the cosmetic is handy to carry. Each of them are made thin, it is easily usable as eye shadow, lip liner, etc.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a pharmaceutical drug which can be used in order to solve a problem in which effective vaccine does not exist, regardless of fact in which role of salivary of Phlebotomus perniciosus and infection of Leishmaniasis are well-known and to induce immune response to organisms causing Leishmaniasis.  &lt;P&gt;SOLUTION: Substantially purified salivary P. ariasi and P. perniciosus polypeptides, and polynucleotides encoding these polypeptides are disclosed. Vectors and host cells including the P. ariasi and P. perniciosus polynucleotides are also disclosed. In one embodiment, a method is disclosed for inducing an immune response to sand fly saliva. In other embodiments, methods for treating or preventing Leishmaniasis are disclosed.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an anti-oxidizing raw material which can exhibit a high anti-oxidizing action, to provide a food or drink, and to provide a method for producing a lignan compound, by which the lignan compound can easily be produced by the fermentation technique.  &lt;P&gt;SOLUTION: This anti-oxidizing raw material is obtained by inoculating a fermentation raw material containing sesamin, sesaminol or a sesaminol glycoside with a microorganism belonging to the genus Aspergillus to subject the raw material to a microorganism fermentation treatment. It is preferable that the anti-oxidizing raw material contains a sesamin dicatechol-form compound or a sesaminol catechol-form compound. It is more preferable that a sesamin catechol-form compound, a sesamin dicatechol-form compound or a sesaminol catechol-form compound is contained as a lignan compound in a larger amount than the fermentation raw material. It is preferable that the fermentation raw material is sesame seeds, roasted sesame, roasted sesame oil, un-roasted sesame salad oil, sesame strained lees, or sesame deodorized scum. A health food as the food or drink contains the anti-oxidizing raw material.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an apparatus and method of drug delivery on a human body surface.  &lt;P&gt;SOLUTION: The formulation comprises a drug, a conversion agent converting the formulation from a less solid phase to a coherent soft solid phase, and a vehicle medium or carrier for the drug and conversion agent. The drug formulation is applied to a human body surface in its less solid phase and is subsequently converted to a soft solid phase while the drug is being delivered through the human body surface. After delivery of the drug is complete, the soft solid formulation can be removed or peeled from the body surface as a coherent solid formulation. The drug formulation controls the drug delivery rate and is removable without leaving a dirty residual formulation on the body surface.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
This invention teaches a method of targeted apheresis that can be used to treat a variety of different diseases including infectious diseases, autoimmune disorders, and reducing circulating biomarkers associated with certain disorders e.g. pre-eclampsia. This invention discloses the use of apheresis membranes as the support matrix upon which one or more different binding agents (e.g. antibodies, aptamers, binding peptides, soluble receptors), and/or ligands (e.g. antigens, serum proteins, hormones, cytokines and cell markers) are attached. During targeted apheresis the patient&#39;s blood will come into contact with one or more of these immobilized binding agents or ligands and any targeted harmful factor in the blood will be bound out of circulation. The cleaned blood is then returned to the patient. Reducing the concentration of the harmful substance in blood will alleviate the symptoms of the disease.
The invention provides novel glucocorticosteroids, glucocorticosteroid-linkers and antibody drug conjugates (ADC&#39;s) comprising an antibody or antibody fragment which binds to an antigen expressed on immune cells, optionally an antigen expressed on human immune cells. In some instances the ADCs comprise an anti-human VISTA (V-region Immunoglobulin-containing Suppressor of T cell Activation(1)) antibody or anti-VISTA antigen-binding antibody fragment which binds to VISTA expressing cells at physiologic pH having a short serum half-life (? 24-72 or 24-48 or 12-24 hours or less in a human VISTA knock-in rodent or ((? 1-3.5 days or less in a human or non-human primate). In some instances these ADCs have a rapid onset of action and are potent for prolonged duration as they are very effectively internalized by immune cells in large amounts where they are cleaved releasing large amounts of active steroid payload. The invention also relates to the use of such ADCs and novel steroids for the treatment of autoimmune, allergic and inflammatory conditions. The invention further relates to methods for reducing the adverse side effects and/or enhancing the efficacy of glucocorticoid receptor agonists by using such ADCs to selectively deliver these anti-inflammatory agents to target immune cells, such as monocytes, neutrophils, B cells, T cells, Tregs, eosinophils, NK cells, macrophages, myeloid cells, et al., and particularly myeloid cells, thereby reducing potential toxicity to non-target cells.
In a method for autologous myocardial implantation treatment, a donor area of a patient containing healthy skeletal muscle is located. Myocyte micro granules are retrieved from the donor area using a retrieval device and either directly implanted into an implantation area of the patient&#39;s myocardium, or they are transferred to an implantation device and then implanted. No intervening cell culturing is performed between myocyte micro granule retrieval and implantation. A retrieval device that may be used to retrieve the myocyte micro granules from the donor area includes one or more extraction probes each having a distal tip adapted to be inserted into the skeletal muscle of the donor area. The retrieval device further includes a retrieval system that causes each distal tip to withdraw a myocyte micro granule upon removal thereof from the donor area. An implantation device that may be used to implant the myocyte micro granules includes a tubular body, an injection tip on the body that is adapted to enter the damaged area and deliver the micro granules, and a plunger within the body for pushing the micro granules through the injection tip. In one configuration of the implantation device that is especially adapted for implantation according to an epicardial approach, the device includes a handle extending laterally from the body for grasping by a medical practitioner when the injection tip is placed in the beating myocardium. In another configuration of the implantation device that is especially adapted for implantation according to a transfemoral approach, the device includes a retractable screen system for blocking myocyte micro granules from leaving the myocardium during implantation.
BISMUTH-CONTAINING COMPOUNDS, COORDINATION POLYMERS, METHODS FOR MODULATING PHARMACOKINETIC PROPERTIES OF BIOLOGICALLY ACTIVE AGENTS, AND METHODS FOR TREATING PATIENTS Bismuth-containing compounds include bismuth and a biologically active agent coordinated to the bismuth. The biologically active agent includes at least one heteroatom configured for coordination with the bismuth. Coordination polymers include a polymer matrix that contains a bismuth-containing compound. Methods for modulating a pharmacokinetic property of a biologically active agent include coordinating the biologically active agent to bismuth to form a bismuth-containing compound, and administering the bismuth-containing compound orally to a patient. Methods for treating Parkinson&#39;s disease, methods for treating hypothyroidism, methods for treating ulcerative colitis, and methods for treating cancer each include administering a bismuth-containing compound to a patient. 7R7040P 1 (CHMattr) P103435 Al J RONIAM 1 o19 cell m / NH2 surfaceI bicadhesive 5-ASA adjuvant cell P- \0 -NH2 surface bloadhesive 5-ASA adjuvant
The invention relates to a new way for guiding a pharmaceutical to specific targets such as microorganisms as bacteria and viruses, tissue cells or tumor cells. The mechanism of targeting is characterized by a number of weakly interacting sites - Kass &lt; ca 104 M-1 - which by cooperation can realize a strong and specific binding to the target which can be e.g. surface antigens on bacteria, viruses or tumor cells. Alternatively the target can be structures of the host cell which can interact with the foreign substance. This weak affinity pharmaceutical can act in different ways by preventing and blocking the binding of the microorganism/tumor cell to its target, host cell or by an improved targeting of the pharmaceutical to the specific binding place. The pharmaceutical system is generally composed of a number of weak affinity sites that is defined and with a specific configuration that a binding to the target is achieved. The combination of affinity sites is obtained by various carriers such as microparticulate substances, macromolecules and low molecular weight substances. In addition, substances are included such as cell poisons, which are used to destroy the invading microorganism/tumor cell.
&lt;P&gt;PROBLEM TO BE SOLVED: To develop a method for producing natural and modified Factor IX.  &lt;P&gt;SOLUTION: Recombinant Factor IX characterized by a high percentage of active protein can be obtained in the milk of transgenic animals incorporating chimeric DNA molecules. Transgenic animals are obtained by introducing DNA encoding the Factor IX into developing embryos so that the foreign DNA is stably incorporated in the DNA of germ line cells of the mature animal. Particularly efficient expression was accomplished by using a chimeric construct comprising a mammary gland-specific promotor, and the Factor IX cDNA lacking the complete or any portion of the 5&#39;-untranslated and 3&#39;-untranslated region, which is substituted with a 5&#39;-end and 3&#39;-end of the mouse whey acidic protein gene. In vitro cell cultures of cells transplanted from the transgenic mammal, methods for producing Factor IX from the cell cultures and methods for treating hemophilia B are also described.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
The cosmetic medium comprises alkyl or alkenyl oligoglycoside of general formula (I), partial glyceride and quaternary hydroxyethyl cellulose polymer. The quaternary hydroxyethyl cellulose polymer is cationically substituted with trimethyl ammonium group, and is modified with dimethyldodecylammonium group hydrophobically. Another cationic polymer, polyethylene glycol and a surfactant are also provided. The partial glyceride is oleic acid monoglyceride. The alkyl or alkenyl oligoglycoside having general formula (I). R1&gt;O-[G]p R1&gt;4-22C alkyl or alkenyl residue, preferably alkyl residue; G : 5 or 6C sugar residue; and p : 1-10. An independent claim is also included for a method for cleaning and caring skin and hair, which involves applying the medium on the skin or scalp.